A Phase Ib/II clinical study is evaluating the efficacy of zanidatamab combined with CAPOX chemotherapy and tislelizumab as a first‐line treatment for advanced HER2‐positive GC/GEJC. This evidence concerns the gene ERBB2 and gastric cancer.